Will I Gain Weight Back When I Stop Ozempic?
In clinical trials, patients regained around two thirds of lost weight within one year of stopping semaglutide. Appetite returns to its pre-treatment baseline when the medication stops. Regained weight tends to return mostly as fat, so someone who lost a meaningful amount of lean mass during treatment can end up with proportionally more fat and less lean tissue than before. Attending to lean mass during treatment shapes what your body is made of, whatever happens with the medication later.
GLP-1 Resource Center
Will I gain weight back when I stop Ozempic?
Weight regain after stopping GLP-1 medications is one of the most documented and least discussed realities of this class of drugs. Studies show that most patients regain a significant proportion of lost weight within one to two years of stopping treatment.
The evidence
Clinical trials following patients after discontinuing semaglutide report that around two thirds of lost weight is typically regained within one year of stopping. The mechanism is straightforward: GLP-1 medications work by suppressing appetite. When the medication is stopped, appetite returns to its pre-treatment baseline. The food noise that the medication quieted returns with it.
Why lean mass matters for regain
Across GLP-1 trials the share of weight lost as lean mass depends on the medication: about 26 percent on tirzepatide, and up to 45 percent on semaglutide, with a class-wide average near 30 percent and reported figures ranging from 20 to 50 percent.* Two things make that figure less alarming than it first reads. In SURMOUNT-1 the placebo group lost the same ratio, 25 percent against 26 percent, so this is weight loss behaving as weight loss rather than the medication doing something unusual. And fat-free mass measured by DXA includes water, glycogen and connective tissue, so it is not skeletal muscle alone.
Regained weight, meanwhile, tends to return mostly as fat. Someone who loses 20kg and regains it after stopping does not get back the lean tissue they lost, which can leave body composition with proportionally more fat and less lean tissue than before treatment. Researchers discuss lean mass as one factor among several in how the body responds after stopping. This is one reason attending to lean mass during treatment is worth the effort, whatever your long-term plan with the medication.
The weight loss plateau connection
Lean mass also comes up in discussions of weight loss plateaus during treatment. In both cases it is one contributor among several rather than the whole story, and in both cases the practical response is the same: adequate protein and movement against resistance, consistently.
The TAKE approach
TAKE Build and TAKE Nourish are formulated to support lean mass during GLP-1 treatment.* The evidence behind creatine is specific about its conditions: a June 2026 JISSN meta-analysis of seven randomised trials in 608 postmenopausal women found gains in lean mass and leg press strength only at 5g or more daily combined with resistance movement, and no effect at 3g or less or without the movement. Creatine does not hold onto muscle on its own. Both products form The Strength System.
These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Always speak with your healthcare provider about medication side effects or medical concerns.